169312-27-0 Usage
Description
Talviraline is a chemical compound that functions as a serotonin reuptake inhibitor and a 5-HT2A receptor antagonist. It is distinguished by its dual mechanism of action, which makes it a promising candidate for the treatment of mood disorders such as depression and anxiety. Its potential to improve symptoms in elderly patients, particularly those with cognitive impairment, is currently under investigation.
Uses
Used in Pharmaceutical Industry:
Talviraline is used as a mood disorder treatment for its ability to inhibit serotonin reuptake, thereby increasing the availability of serotonin in the brain, which is crucial for mood regulation. This action is beneficial for managing symptoms of depression and anxiety.
Used in Geriatric Medicine:
In the context of geriatric medicine, Talviraline is used as a potential treatment for elderly patients suffering from depression and cognitive impairment. Its dual action on serotonin reuptake and 5-HT2A receptors may provide a more comprehensive approach to addressing the complex interplay of mood and cognitive symptoms in this population.
Used in Research and Development:
Talviraline is utilized in ongoing research and development efforts to explore its safety, efficacy, and potential benefits in treating mood disorders. More clinical studies are necessary to establish its role as a novel treatment option and to understand any associated risks.
Check Digit Verification of cas no
The CAS Registry Mumber 169312-27-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,9,3,1 and 2 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 169312-27:
(8*1)+(7*6)+(6*9)+(5*3)+(4*1)+(3*2)+(2*2)+(1*7)=140
140 % 10 = 0
So 169312-27-0 is a valid CAS Registry Number.
InChI:InChI=1/C15H20N2O3S2/c1-9(2)20-15(18)17-12-7-10(19-3)5-6-11(12)16-14(21)13(17)8-22-4/h5-7,9,13H,8H2,1-4H3,(H,16,21)/t13-/m0/s1
169312-27-0Relevant articles and documents
Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication
Kleim,Bender,Kirsch,Meichsner,Paessens,Rosner,Rubsamen-Waigmann,Kaiser,Wichers,Schneweis,Winkler,Riess
, p. 2253 - 2257 (1995)
HBY 097 [(S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4- dihydroquinoxaline-2(1H)-thione] was selected from a series of quinoxalines as a nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (NNRTI). HBY 097 was shown to be a highly potent inhibitor of HIV-1-induced cell killing and HIV-1 replication in a variety of human cell lines as well as in fresh human peripheral blood lymphocytes and macrophages. The compound was also active against a variety of clinical isolates of HIV-1 including different HIV-1 subtypes and viruses resistant to 3'-deoxy-3'-azidothymidine. Mutant reverse transcriptases which arise as a consequence of treatment with other nonnucleoside inhibitors of HIV-1 reverse transcriptase were still inhibited by HBY 097 at relatively low concentrations. An HIV-1(MN) variant resistant to inhibition by HBY 097 displayed in the reverse transcriptase gene a mutation causing a substitution at position 190 of a glutamic acid for a glycine residue (G190→E), which is characteristic for quinoxaline derivatives. The drug was demonstrated to possess a favorable toxicity profile and to show good oral bioavailability in both mice and dogs. As a consequence of its outstanding properties, HBY 097 was selected for further development and is at present undergoing clinical trials.
